August 06, 2012 at 06:59 AM EDT
PharmaEngine Acquires China Rights to Nanobiotix Cancer Product
PharmaEngine of Taiwan acquired Asia-Pacific rights (including China) to a radiology-enhancing nanomedicine product from Nanobiotix S.A., a French company. NBTXR3 is currently undergoing a Phase I study trial in Europe as a treatment for soft tissue sarcoma. According to Nanobiotix, NBTXR3 increases the effect of radiation by a factor of three in mouse models without affecting nearby tissue. More details.... Stock Symbol: (TWO: 4162) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here